NewLimit

NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This process involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing initially on rejuvenating the immune system and liver. The company uses advanced technologies like single-cell genomics and machine learning to identify aging markers and create interventions that reverse these changes. NewLimit targets the healthcare market, serving pharmaceutical companies, healthcare providers, and individuals seeking anti-aging treatments. Its goal is to create a new class of medicines that significantly increase the period of life spent in good health.